



SAVING LIVES AND ADVANCING  
RESEARCH BY EMPOWERING  
THOSE LIVING WITH AND  
AT RISK FOR LUNG CANCER.

[LungCancerAlliance.org](http://LungCancerAlliance.org)

1700 K Street NW, Ste 660  
Washington, DC 20006

January 22, 2019

The Honorable Jerry Moran  
United States Senate  
309 Hart Senate Office Building  
Washington, DC 20510

The Honorable Tina Smith  
United States Senate  
521 Dirksen Senate Office Building  
Washington, DC 20510

Dear Senator Moran and Senator Smith:

On behalf of Lung Cancer Alliance (LCA), a leading non-profit health organization dedicated solely to saving lives and improving quality of life for those living with or at risk for lung cancer and as a Member of the Coalition to Improve Access to Cancer Care, I am writing to thank you for introducing Senate companion legislation to H.R. 1409, The Cancer Drug Parity Act.

As LCA is working to provide a more compassionate and comprehensive public health strategy for lung cancer, we believe in affordable access to care, which allow patients to have quality, longer lives, without coverage prohibitive medical expenses.

Currently there is strong bipartisan support to modernize insurance benefit designs so that patient out-of-pocket expenses for oral drugs are not subject to arbitrary insurance design that will deny patients optimal therapy for their condition. While states are passing laws, federal legislation is needed to ensure that any health care plan currently covering cancer treatment provide patients with access to cancer medications taken by pill at a similar out-of-pocket cost as cancer medications administered by IV, port or injection at a doctor's office.

At such a promising time when more treatment options are becoming available for lung cancer, LCA has made it a priority to ensure that our community understands and has access to the best treatment options that improve outcomes.

With strong support, we endorse the legislation and look forward to working with you as part of the Coalition to Improve Access to Cancer Care to advance the Cancer Drug Parity Act. Please

feel free to contact Elridge Proctor, Director of Government Affairs & Public Policy at 202-742-1427 or [Eproctor@lungcanceralliance.org](mailto:Eproctor@lungcanceralliance.org) with any questions.

Sincerely,

A handwritten signature in black ink, reading "Laurie Fenton-Ambrose". The signature is written in a cursive style with a large initial "L".

Laurie Fenton-Ambrose  
President and CEO  
Lung Cancer Alliance

